GenomicsbioRxivPreprint
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer
Anton Mikhailovich Safonov, Antonio Marra, Chaitanya Bandlamudi…·Pedram Razavi
The paper identifies how germline and somatic mutations interact to cause resistance to CDK4/6 inhibitors in breast cancer and proposes a sequential treatment strategy using PARP inhibitors.
18 citations